The Library
GLO1-a novel amplified gene in human cancer
Tools
Santarius, Thomas, Bignell, Graham R., Greenman, Chris D., Widaa, Sara, Chen, Lina, Mahoney, Claire L., Butler, Adam, Edkins, Sarah, Waris, Sahar, Thornalley, Paul J., Futreal, P. Andrew and Stratton, Michael R. (2010) GLO1-a novel amplified gene in human cancer. Genes Chromosomes & Cancer, Vol.49 (No.8). pp. 711-725. doi:10.1002/gcc.20784 ISSN 1045-2257.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1002/gcc.20784
Abstract
To identify a novel amplified cancer gene a systematic screen of 975 human cancer DNA samples, 750 cell lines and 225 primary tumors, using the Affymetrix 10K SNP microarray was undertaken. The screen identified 193 amplicons. A previously uncharacterized amplicon located on 6p21.2 whose 1 Mb minimal common amplified region contained eight genes (GLO1, DNAH8, GLPIR, C6orf64, KCNKS, KCNK17, KCNK16, and C6orf102) was further investigated to determine which gene(s) are the biological targets of this amplicon. Real time quantitative PCR (qPCR) analysis of all amplicon 6p21.2 genes in 618 human cancer cell lines identified GLO1, encoding glyoxalase 1, to be the most frequently amplified gene [twofold or greater amplification in 8.4% (49/536) of cancers]. Also the association between amplification and overexpression was greatest for GLO1. RNAi knockdown of GLO1 had the greatest and most consistent impact on cell accumulation and apoptosis. Cell lines with GLO1 amplification were more sensitive to inhibition of GLO1 by bromobenzylglutathione cyclopentyl diester (BBGC). Subsequent qPCR of 520 primary tumor samples identified twofold and greater amplification of GLO1 in 8/37 (22%) of breast, 12/71 (17%) of sarcomas, 6/53 (11.3%) of nonsmall cell lung, 2/23 (8.7%) of bladder, 6/93 (6.5%) of renal and 5/83 (6%) of gastric cancers. Amplification of GLO1 was rare in colon cancer (1/35) and glioma (1/94). Collectively the results indicate that GLO1 is at least one of the targets of gene amplification on 6p21.2 and may represent a useful target for therapy in cancers with GLO1 amplification. (C) 2010 Wiley-Liss, Inc.
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) Q Science > QH Natural history > QH426 Genetics |
||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016) Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
Journal or Publication Title: | Genes Chromosomes & Cancer | ||||
Publisher: | Wiley-Liss | ||||
ISSN: | 1045-2257 | ||||
Official Date: | August 2010 | ||||
Dates: |
|
||||
Volume: | Vol.49 | ||||
Number: | No.8 | ||||
Number of Pages: | 15 | ||||
Page Range: | pp. 711-725 | ||||
DOI: | 10.1002/gcc.20784 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Access rights to Published version: | Restricted or Subscription Access | ||||
Funder: | Wellcome Trust, Michael and Betty Kadoorie Cancer Genetics Research Programme | ||||
Grant number: | 077012/Z/05/Z |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |